Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update
CGTXCognition Therapeutics(CGTX) Newsfilter·2024-05-07 19:30
  • Topline Results from SHINE Study in Mild-to-Moderate Alzheimer's Expected Mid-2024 -- SHIMMER Study in Dementia with Lewy Bodies Completed Enrollment of 130 Participants - PURCHASE, N.Y., May 07, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the "Company" or "Cognition"), today reported financial results for the first quarter ended March 31, 2024, and provided a business update. "During t ...